Most Read Articles
6 months ago

Associate Professor Ng Lee Ching, Director of the Environmental Health Institute (EHI) at the National Environment Agency (NEA), Singapore, speaks about the role of primary care physicians and government agencies in preventing dengue epidemics.

Yesterday
Venlafaxine (VLX) appears to be effective and well-tolerated in patients with neuropathic pain, according to the results of a literature review.
2 months ago
New drug applications approved by US FDA as of 1 - 15 April 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Gayle Fischer, 3 years ago

A 12-year-old boy presents with sudden onset of blistering lesions on his arms and legs (Figure 1), occurring a few days after he developed a typical cold sore on his upper lip.

Tolterodine, solifenacin, oxybutynin use tied to increased risk of dementia

2 months ago

Subsequent dementia is associated with taking tolterodine, solifenacin and particularly oxybutynin in patients with diabetes mellitus, a new study shows.

The study retrieved records of 10,938 patients who had received at least one type of oxybutynin, tolterodine or solifenacin from the Taiwan National Health Insurance Research Database. An age-, sex- and index date-matched control cohort was established on a 1:1 ratio. Those diagnosed with dementia before the index date or within 180 days were excluded.

Comorbidities included in the analysis were hypertension, lipid disorders, atrial fibrillation, chronic kidney diseases, coronary artery disease and heart failure.

Dementia was reported in 7,774 at the end of the follow-up period. For the oxybutynin, solifenacin and tolterodine groups, the 6-year dementia rates were 3.9, 4.3 and 2.2 percent, respectively. These rates were significantly different compared with the control group (1.2 percent; p<0.001).

After age- and sex-matching, only 2,540 patients were eligible for analysis. The 6-year dementia rates for this group decreased for oxybutynin (3.0 percent) and solifenacin (3.5 percent). Interestingly, the rate increased in controls (2.4 percent) to a level that was higher than that reported in tolterodine users (2.3 percent).

According to the failure curve, dementia was significantly more likely to occur in patients who took oxybutynin, solifenacin or tolterodine (p<0.001 for all).

After adjusting for confounders, the competing-risk regression model showed that those who received oxybutynin (adjusted hazard ratio [aHR], 2.35; 95 percent CI, 1.96 to 2.81), solifenacin (aHR, 2.16; 1.81 to 2.58) and tolterodine (aHR, 2.24; 1.85 to 2.73) were at higher risks of dementia, with death as the competing event. Of the three drugs, solifenacin showed the lowest risk.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
6 months ago

Associate Professor Ng Lee Ching, Director of the Environmental Health Institute (EHI) at the National Environment Agency (NEA), Singapore, speaks about the role of primary care physicians and government agencies in preventing dengue epidemics.

Yesterday
Venlafaxine (VLX) appears to be effective and well-tolerated in patients with neuropathic pain, according to the results of a literature review.
2 months ago
New drug applications approved by US FDA as of 1 - 15 April 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Gayle Fischer, 3 years ago

A 12-year-old boy presents with sudden onset of blistering lesions on his arms and legs (Figure 1), occurring a few days after he developed a typical cold sore on his upper lip.